Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis
NCT ID: NCT00333411
Last Updated: 2014-06-19
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
360 participants
Study Classification
INTERVENTIONAL
Study Start Date
2006-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this clinical study is to determine the effectiveness, pharmacokinetics and safety of several doses of BIRT 2584 XX (100mg, 300mg and 500mg) taken once daily in the treatment of moderate to severe plaque-type psoriasis. This new medicine will be compared to a so-called placebo medicine over 12 weeks with a 12 weeks treatment extension possible.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906
Psoriasis
COMPLETED
PHASE2
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
NCT01782664
Psoriasis
COMPLETED
PHASE2
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
NCT03835481
Psoriasis
TERMINATED
PHASE2
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
NCT05377944
Plaque Psoriasis
COMPLETED
PHASE3
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986
Plaque Psoriasis
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The proposed study is a phase 2a/b international multicentre clinical trial. The general aim of this study is to investigate the safety and efficacy (clinical proof of concept) of three different doses (100 mg, 300 mg, or 500 mg) of BIRT 2584 XX tablets administered orally once daily compared to placebo tablets for the treatment of patients with moderate to severe plaque-type psoriasis patients who are candidates for systemic treatment or phototherapy. This study may also provide dose-finding information for future pivotal studies.
The response to treatment will be measured for all patients in the study after 12 weeks of treatment using the PASI as the primary endpoint, and also the sPGA. Both instruments evaluate the clinical severity of plaque-type psoriatic lesions. Training on PASI and sPGA assessment will be provided in order to decrease inter-observer variability. The sPGA is thus to be validated for future phase 3 trials.
After 12 weeks of treatment, only those patients with a response equivalent or better than PASI50 and with a satisfactory safety experience will enter a 12 week extension of the treatment period. The total time of exposure to study drug in this subgroup of patients will be 24 weeks. All other study patients will terminate treatment with study drug after 12 weeks.
In addition, the durability of remission/response, and the occurrence of any relapse or rebound during the treatment with study drug and after the end of treatment will be assessed in an 8 weeks follow-up period. The follow-up period is applicable to all study participants who have taken at least one dose of study drug. It initiates after the last dose of study medication has been taken, irrespective of the duration of the patients actual treatment period.
The trial will use a modified dose-escalation scheme. The randomisation to the 500 mg treatment arm will initiate only after a Data Safety Monitoring Board (DSMB) decision on the safety of the other treatment arms. An IVRS will be used for randomisation in this trial.
Ninety (90) patients are required per dose group. With four groups and an overall 1:1:1:1 randomisation scheme, a total of 360 eligible patients are planned to be randomised to treatment.
Study Hypothesis:
Psoriasis is a chronic inflammatory disease that leads to skin sores. These skin sores are dependent on the rate of growth of the skin which is driven by an underlying corresponding degree of local inflammation. The skin inflammation is caused by different cell types that move from the blood vessels into the skin. This cell movement is a result of interaction of different proteins. One of these proteins is called LFA-1 (Lymphocyte Function Associated Antigen 1). LFA-1 is then a promising target for psoriasis therapy. BIRT 2584 XX will block the passage of these inflammatory cells from the blood to the skin by blocking LFA-1, and thus indirectly block the inflammatory process. BIRT 2584 XX can also block the activation of local inflammatory cells, which altogether may reduce the signs and symptoms of psoriasis.
A dose-dependent effect of BIRT 2584 XX was observed on a set of markers in the blood that are believed to correlate with the severity of the inflammatory process leading to psoriasis.
Comparison(s):
In this clinical study, BIRT 2584 XX in a dose of 100 mg, 300 mg or 500 mg, or placebo will be given once daily. Patients will receive the same treatment throughout the study.
Patients will have a 1 in 4 chance (25%) of being allocated to placebo treatment. The placebo is identical in appearance compared to any one of the three dose groups with BIRT 2584 XX, but does not contain any active ingredient. The purpose of a comparison with placebo is to ensure a more reliable assessment of the therapeutic effect and of the side effects of BIRT 2584 XX.
The response to treatment will be measured for all patients in the study after 12 weeks of treatment using the PASI as the primary endpoint, and also the sPGA. Both instruments evaluate the clinical severity of plaque-type psoriatic lesions. Training on PASI and sPGA assessment will be provided in order to decrease inter-observer variability. The sPGA is thus to be validated for future phase 3 trials.
After 12 weeks of treatment, only those patients with a response equivalent or better than PASI50 and with a satisfactory safety experience will enter a 12 week extension of the treatment period. The total time of exposure to study drug in this subgroup of patients will be 24 weeks. All other study patients will terminate treatment with study drug after 12 weeks.
In addition, the durability of remission/response, and the occurrence of any relapse or rebound during the treatment with study drug and after the end of treatment will be assessed in an 8 weeks follow-up period. The follow-up period is applicable to all study participants who have taken at least one dose of study drug. It initiates after the last dose of study medication has been taken, irrespective of the duration of the patients actual treatment period.
The trial will use a modified dose-escalation scheme. The randomisation to the 500 mg treatment arm will initiate only after a Data Safety Monitoring Board (DSMB) decision on the safety of the other treatment arms. An IVRS will be used for randomisation in this trial.
Ninety (90) patients are required per dose group. With four groups and an overall 1:1:1:1 randomisation scheme, a total of 360 eligible patients are planned to be randomised to treatment.
Study Hypothesis:
Psoriasis is a chronic inflammatory disease that leads to skin sores. These skin sores are dependent on the rate of growth of the skin which is driven by an underlying corresponding degree of local inflammation. The skin inflammation is caused by different cell types that move from the blood vessels into the skin. This cell movement is a result of interaction of different proteins. One of these proteins is called LFA-1 (Lymphocyte Function Associated Antigen 1). LFA-1 is then a promising target for psoriasis therapy. BIRT 2584 XX will block the passage of these inflammatory cells from the blood to the skin by blocking LFA-1, and thus indirectly block the inflammatory process. BIRT 2584 XX can also block the activation of local inflammatory cells, which altogether may reduce the signs and symptoms of psoriasis.
A dose-dependent effect of BIRT 2584 XX was observed on a set of markers in the blood that are believed to correlate with the severity of the inflammatory process leading to psoriasis.
Comparison(s):
In this clinical study, BIRT 2584 XX in a dose of 100 mg, 300 mg or 500 mg, or placebo will be given once daily. Patients will receive the same treatment throughout the study.
Patients will have a 1 in 4 chance (25%) of being allocated to placebo treatment. The placebo is identical in appearance compared to any one of the three dose groups with BIRT 2584 XX, but does not contain any active ingredient. The purpose of a comparison with placebo is to ensure a more reliable assessment of the therapeutic effect and of the side effects of BIRT 2584 XX.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Psoriasis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BIRT 2584 XX high dose
Group Type
EXPERIMENTAL
BIRT 2584 XX
Intervention Type
DRUG
BIRT 2584 XX medium dose
Group Type
EXPERIMENTAL
BIRT 2584 XX
Intervention Type
DRUG
BIRT 2584 XX low dose
Group Type
EXPERIMENTAL
BIRT 2584 XX
Intervention Type
DRUG
Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BIRT 2584 XX
Intervention Type
DRUG
Placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age 18 to 75, males or females
2. Patients with stable moderate to severe plaque-type psoriasis involving ?10% body surface area, with minimum disease severity PASI ?10 and with static PGA of at least moderate (score of at least 3) at screening visit
3. Psoriasis disease duration of at least 6 months prior to screening
4. Patients must be candidates for systemic psoriasis treatment or phototherapy
5. Patient must give informed consent and sign an approved consent form prior to any study procedures, including wash out of prohibited medications (Patients participating in the PK sub-study will sign an additional consent form. Refusal to participate in the sub-study will not exclude from participation in the main trial)
Exclusion\_Criteria:
1. Patients with primary guttatae, erythrodermic, or pustular psoriasis
2. Patients who have previously discontinued efalizumab treatment due to lack of efficacy
3. Patients using treatments that could interfere with the primary endpoint of the study (cf. protocol section 4.2.2.1)
4. Patients on treatment with warfarin, paracetamol (acetaminophen), some NSAIDs, some antidepressants, medications known to induce or inhibit CYP3A4, or any other concomitant medication where potential drug-drug interactions with BIRT 2584 XX could either result in decreased efficacy or an unacceptable benefit-risk assessment, and where replacement of that concomitant medication with a safe equivalent drug is not possible (cf. protocol section 4.2.2.2 and the Investigator Site File).
5. Patients with active liver disease or history of any significant liver disease.
6. Any clinically significant illness or unstable disease which according to investigator judgement may either put the patient at risk because of participation in the study or may influence the results of the study or the patients ability to participate.
7. Patient with serum creatinine and/or white blood cell count \>1.5 x ULN at screening.
(Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
8. Patients with ALT, AST and/or total bilirubin \> 1.5xULN at screening (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
9. Abnormal values of other laboratory parameters at screening that would define a clinically significant disease as described in # 6 above (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
10. Positive testing at screening, or history of HIV or hepatitis B or hepatitis C, or any serious infection (requiring hospitalisation or parenteral antibiotic therapy) in the past 3 months prior to screening
11. History of malignancy in the past 5 years or suspicion of active malignant disease except treated cutaneous squamous cell or basal cell carcinoma
12. Patients with the following findings at the screening visit that could interfere with cardiac repolarisation:
* marked baseline prolongation of QT/QTc interval as measured on ECG (e.g. QTc interval \>450ms);
* history of additional risk factors for Torsade de pointe (e.g. heart failure, - hypokalemia, family history of long QT syndrome);
* use of concomitant medications that prolong the QT/QTc interval
13. History of drug or alcohol abuse within the past two years
14. Pre-menopausal (last menstruation \≤ 1 year prior to screening) sexually active woman who:
* is pregnant or nursing
* is of child bearing potential and not practicing acceptable methods of birth control, or does not plan to continue practising an acceptable method throughout the study (acceptable methods of birth control include surgical sterilisation, intrauterine devices, double barrier, male partner sterilisation, but not hormonal contraceptives\*\*) \[A negative serum pregnancy test at screening (Visit 1) and a negative urine test prior to randomisation (Visit 2) are required\]
15. Patient not willing to avoid excess sun exposure during the trial duration
16. Patients who have taken an investigational drug, within the last 4 weeks or 5 half lives (which ever is greater) prior to randomisation \[Patients who have been treated with any investigational antibody or fusion protein within the past 12 weeks before randomisation are excluded\]
17. Known allergy to BIRT 2584 XX or to the excipients used for tablet formulation
18. Body mass index \> 34 kg/m2 at screening
2. Patients with stable moderate to severe plaque-type psoriasis involving ?10% body surface area, with minimum disease severity PASI ?10 and with static PGA of at least moderate (score of at least 3) at screening visit
3. Psoriasis disease duration of at least 6 months prior to screening
4. Patients must be candidates for systemic psoriasis treatment or phototherapy
5. Patient must give informed consent and sign an approved consent form prior to any study procedures, including wash out of prohibited medications (Patients participating in the PK sub-study will sign an additional consent form. Refusal to participate in the sub-study will not exclude from participation in the main trial)
Exclusion\_Criteria:
1. Patients with primary guttatae, erythrodermic, or pustular psoriasis
2. Patients who have previously discontinued efalizumab treatment due to lack of efficacy
3. Patients using treatments that could interfere with the primary endpoint of the study (cf. protocol section 4.2.2.1)
4. Patients on treatment with warfarin, paracetamol (acetaminophen), some NSAIDs, some antidepressants, medications known to induce or inhibit CYP3A4, or any other concomitant medication where potential drug-drug interactions with BIRT 2584 XX could either result in decreased efficacy or an unacceptable benefit-risk assessment, and where replacement of that concomitant medication with a safe equivalent drug is not possible (cf. protocol section 4.2.2.2 and the Investigator Site File).
5. Patients with active liver disease or history of any significant liver disease.
6. Any clinically significant illness or unstable disease which according to investigator judgement may either put the patient at risk because of participation in the study or may influence the results of the study or the patients ability to participate.
7. Patient with serum creatinine and/or white blood cell count \>1.5 x ULN at screening.
(Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
8. Patients with ALT, AST and/or total bilirubin \> 1.5xULN at screening (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
9. Abnormal values of other laboratory parameters at screening that would define a clinically significant disease as described in # 6 above (Repeat laboratory is allowed once between screening and randomisation prior to excluding the patient)
10. Positive testing at screening, or history of HIV or hepatitis B or hepatitis C, or any serious infection (requiring hospitalisation or parenteral antibiotic therapy) in the past 3 months prior to screening
11. History of malignancy in the past 5 years or suspicion of active malignant disease except treated cutaneous squamous cell or basal cell carcinoma
12. Patients with the following findings at the screening visit that could interfere with cardiac repolarisation:
* marked baseline prolongation of QT/QTc interval as measured on ECG (e.g. QTc interval \>450ms);
* history of additional risk factors for Torsade de pointe (e.g. heart failure, - hypokalemia, family history of long QT syndrome);
* use of concomitant medications that prolong the QT/QTc interval
13. History of drug or alcohol abuse within the past two years
14. Pre-menopausal (last menstruation \≤ 1 year prior to screening) sexually active woman who:
* is pregnant or nursing
* is of child bearing potential and not practicing acceptable methods of birth control, or does not plan to continue practising an acceptable method throughout the study (acceptable methods of birth control include surgical sterilisation, intrauterine devices, double barrier, male partner sterilisation, but not hormonal contraceptives\*\*) \[A negative serum pregnancy test at screening (Visit 1) and a negative urine test prior to randomisation (Visit 2) are required\]
15. Patient not willing to avoid excess sun exposure during the trial duration
16. Patients who have taken an investigational drug, within the last 4 weeks or 5 half lives (which ever is greater) prior to randomisation \[Patients who have been treated with any investigational antibody or fusion protein within the past 12 weeks before randomisation are excluded\]
17. Known allergy to BIRT 2584 XX or to the excipients used for tablet formulation
18. Body mass index \> 34 kg/m2 at screening
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim Study Coordinator
Role: STUDY_CHAIR
BI France S.A.S.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatologie Kliniek
Antwerp, , Belgium
Site Status
Hôpital Erasme
Brussels, , Belgium
Site Status
UZ Antwerpen
Edegem, , Belgium
Site Status
Boehringer Ingelheim Investigational Site
Calgary, Alberta, Canada
Site Status
Boehringer Ingelheim Investigational Site
Vancouver, British Columbia, Canada
Site Status
Eastern Canada Cutaneous Research Associates Ltd.
Halifax, Nova Scotia, Canada
Site Status
Boehringer Ingelheim Investigational Site
London, Ontario, Canada
Site Status
Boehringer Ingelheim Investigational Site
Markham, Ontario, Canada
Site Status
Boehringer Ingelheim Investigational Site
Waterloo, Ontario, Canada
Site Status
Innovaderm Research Inc.
Montreal, Quebec, Canada
Site Status
Dr. Wayne Carey
Montreal, Quebec, Canada
Site Status
Boehringer Ingelheim Investigational Site
Montreal, Quebec, Canada
Site Status
Boehringer Ingelheim Investigational Site
Sainte-Foy, Quebec, Canada
Site Status
Marselisborg Centret
Aarhus C, , Denmark
Site Status
Amtssygehuset i Gentofte
Hellerup, , Denmark
Site Status
Odense Universitetshospital
Odense C, , Denmark
Site Status
Päijät-Hämeen keskussairaala
Lahti, , Finland
Site Status
Hôpital Saint Jacques
Besançon, , France
Site Status
Hôpital Dupuytren
Limoges, , France
Site Status
Hôpital de L'Archet
Nice, , France
Site Status
Hôpital Saint Louis
Paris, , France
Site Status
CHU - Hôpital Nord
Saint-Priest-en-Jarez, , France
Site Status
Hôpital Nord
Saint-Priest-en-Jarez, , France
Site Status
Charite, Campus Virchow-Klinikum
Berlin, , Germany
Site Status
St. Josef-Hospital
Bochum, , Germany
Site Status
Universitätsklinikum an der TU Dresden
Dresden, , Germany
Site Status
Universitätsklinikum Erlangen
Erlangen, , Germany
Site Status
Universitäts-Hautklinik
Freiburg im Breisgau, , Germany
Site Status
Universitätsklinikum Schleswig-Holstein
Kiel, , Germany
Site Status
Otto-von-Guericke-Universität Magdeburg
Magdeburg, , Germany
Site Status
Boehringer Ingelheim Investigational Site
Mahlow, , Germany
Site Status
Johannes Gutenberg-Universität Mainz
Mainz, , Germany
Site Status
Universitätsklinikum Münster
Münster, , Germany
Site Status
Universitätsklinikum Ulm
Ulm, , Germany
Site Status
Academic Medical Centre
Amsterdam, , Netherlands
Site Status
University Medical Centre Nijmegen St. Radboud West
Nijmegen, , Netherlands
Site Status
Boehringer Ingelheim Investigational Site
Barcelona, , Spain
Site Status
Servicio de Dermatología
Madrid, , Spain
Site Status
Servicio de Dermatología
Madrid, , Spain
Site Status
Karolinska Universitetssjukhuset Solna
Stockholm, , Sweden
Site Status
Aberdeen Royal Infirmary, Department of Dermatology
Aberdeen, , United Kingdom
Site Status
Cardiff University, Dermatology Department
Cardiff, , United Kingdom
Site Status
Western Infirmary, Department of Dermatology
Glasgow, , United Kingdom
Site Status
Royal Free Hospital, Dermatology Department,
London, , United Kingdom
Site Status
Skin Therapy Research Unit, St John's Inst of Dermatolology
London, , United Kingdom
Site Status
George Eliot Hospital, Dermatology Department
Nuneaton, , United Kingdom
Site Status
Hope Hospital, The Dermatology Centre,
Salford, , United Kingdom
Site Status
Royal South Hants Hospital, Dept of Dermatology
Southampton, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Belgium
Canada
Denmark
Finland
France
Germany
Netherlands
Spain
Sweden
United Kingdom
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1206.5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
BTT1023 in Psoriasis
NCT00871598
COMPLETED
PHASE1
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209
COMPLETED
PHASE2
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00292396
COMPLETED
PHASE2
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422
COMPLETED
PHASE2
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301
COMPLETED
PHASE2
Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03463187
COMPLETED
PHASE1/PHASE2
This Study is Done in Patients With Plaque Psoriasis and Tests How Well They Tolerate BI 730357 and How Effective it is
NCT03635099
COMPLETED
PHASE2
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
NCT00333034
COMPLETED
PHASE3
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
NCT01690299
COMPLETED
PHASE3
Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00626002
COMPLETED
PHASE3
Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis
NCT00317499
COMPLETED
PHASE3
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01072383
COMPLETED
PHASE2
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT05364554
COMPLETED
PHASE2
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
NCT03145948
TERMINATED
PHASE1
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964
COMPLETED
PHASE3
A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis
NCT06875934
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
NCT04316585
COMPLETED
PHASE1
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT07265284
RECRUITING
PHASE3
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
NCT05223868
COMPLETED
PHASE2
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00710580
COMPLETED
PHASE3
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
NCT03329885
TERMINATED
PHASE1/PHASE2
A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis
NCT05357755
COMPLETED
PHASE2
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
NCT07130604
RECRUITING
PHASE3
VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
NCT05655299
TERMINATED
PHASE2
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
NCT07251998
RECRUITING
PHASE2